Sanofi Pasteur To Launch Meningococcal Vaccine In China
This article was originally published in PharmAsia News
Sanofi Pasteur will soon launch its meningococcal polysaccharide vaccine A and C (Menomune A/C) in China, heating up the market after meningococcal vaccine was included in the country's expanded immunity program. According to a China CDC official, as domestic meningococcal vaccine cannot meet the expanded demand, approval of Menomune A/C will provide consumers with more choices. Although local vaccines costing some 20 yuan are administered free for children, the Sanofi Pasteur product will be sold at 128 yuan. Menomune A/C is the only imported meningococcal vaccine approved in China to date and the company targets sales of 2 million doses in the next five years. (Click here for more - Chinese Language)
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.